FdaApplication
BLA 761344
Identifiers
- fda_app_no: BLA761344
Properties
| Property | Value |
|---|---|
| applicant_name | Amgen Inc. |
| application_type | BLA |
| approval_date | 2024-05-16 |
Revenue by product
IMDELLTRA
| Period | Revenue |
|---|---|
| Q2 2026 | $288.0M |
| Q1 2026 | $258.0M |
| Q2 2025 | $134.0M |
| Q1 2025 | $81.0M |
Revenue as this company reported it for this product. A combination product's amount is stated once, for the product, and never divided across its ingredients.
Products (2)
| Product | Active ingredient | Strength | Dosage form |
|---|---|---|---|
| IMDELLTRA | TARLATAMAB-DLLE | 10MG | Injection |
| IMDELLTRA | TARLATAMAB-DLLE | 1MG | Injection |
2 products